Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults

Gonzalo-Daganzo, Rosa M.; Regidor, C; Martín-Donaire, Trinidad; Rico, Miguel A.; Bautista, Guiomar; Krsnik, Isabel; Forés, Rafael; Ojeda, Emilio; Sanjuán, I; García-Marco, José A.; Navarro, Belén; Gil, Santiago; Sánchez, Rocío; Panadero, Nuria; Gutiérrez, Yolanda; García-Berciano, Miguel; Pérez, Núria Teixidó; Millán, Isabel; Cabrera, Rafael; Fernández, M.N.

doi:10.1080/14653240902807018

Cited by 115 publications

(88 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MSC is a heterogeneous cellular population consisting of mesenchymal stem cells and previous studies showed that the MSC plays important role in supporting hematopoietic stem cells (HSC) engraftment after transplantation [1,2] . Moreover, recent studies support the potential role of MSC as an immune modulator, and MSC play important role in prevention and treatment of graft-versus-host disease (GVHD) [3][4][5][6][7][8][9][10][11][12] . These MSC applied clinically were all in-vitro expanded.…”

Section: Introductionmentioning

confidence: 99%

Factors affecting mesenchymal stromal cells yield from bone marrow aspiration

Wong

Chan

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective: This study was to investigate the variables in bone marrow harvesting procedure and individual donor factors which can potentially affect the yield of mesenchymal stromal cells (MSC).Methods: We determined the yield of MSC from bone marrow under different clinical conditions by comparing the MSC colony numbers from: (1) donors of different ages; (2) healthy donors and patients with leukemia; (3) bone marrow aspirated at different time points during marrow harvesting; (4) bone marrow harvested by different needles.Results: During the process of harvesting, the number of MSC significantly decreased with increase number of aspiration, from 675/ml at the initial decreased to 60/ml after 100 ml bone marrow aspirated, and 50/ml after 200 ml bone marrow aspirated. The number of MSC retrieved from leukemia patients (99/ml bone marrow) was significantly lower than that of healthy donors (708/ml bone marrow). However, there was no significant difference in growth rate. There was no significant age-related difference of MSC yielded from donors <55 years. And there was no significant difference in MSC number between the samples from single end-holed needle and those from multiple-side-hole needle.Conclusion: The optimal bone marrow samples for MSC collection should be obtained earlier in the process of harvesting procedure. Bone marrow from donors <55 years was equally good as MSC sources. The autologous MSC from leukemia patients can be utilized for in-vitro MSC expansion.

show abstract

Section: Introductionmentioning

confidence: 99%

Factors affecting mesenchymal stromal cells yield from bone marrow aspiration

Wong

Chan

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

show abstract

“…16 In adult patients receiving UCBT with coinfusion of third-party donor-mobilized HCs, MSC administration at the time of transplantation had no effect on the kinetics of UCB cell engraftment, as well as on GvHD prevention. 51 Altogether, these data indicate that co-transplantation of HCs and MSCs is safe, while there is still uncertainty about a real efficacy of MSCs on promoting engraftment of donor cells and accelerating the speed of hematological recovery. In particular, in some contexts (such as T-cell-depleted human leukocyte antigen-disparate allograft from a 35,41 the transplantability and sustained engraftment of MSCs in human beings are largely controversial, probably being unusual events.…”

Section: Clinical Trials Of Msc Infusion To Promote Engraftmentmentioning

confidence: 99%

“…15,16,[47][48][49][50][51] Indeed, to date no adverse effects have been registered after MSC administration, although a longer follow-up is necessary to draw definitive conclusions on potential late adverse events. The execution of large, multicenter, randomized clinical trials specifically addressing response to MSC therapy in terms of prevention of graft failure and facilitation/acceleration of hematopoietic recovery, in comparison with conventional treatment modalities, is warranted to show the real value of this approach.…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation?

Bernardo

Cometa

Locatelli

2011

Bone Marrow Transplant

View full text Add to dashboard Cite

“…No adverse events were reported with MSC infusion. Two patients in the MSC group developed steroid-refractory grade II acute GVHD, but therapeutic infusion of MSCs resulted in complete resolution of the GVHD (Gonzalo-Daganzo et al 2009 ) .…”

Section: Co-transplantation Of Umbilical Cord Blood Stem Cells and Mementioning

confidence: 99%